The present disclosure provides engineered adenosine kinase polypeptides, and recombinant polynucleotides encoding the engineered adenosine kinases. The present disclosure further provides method of using the engineered adenosine kinases.

The present invention provides antisense oligonucleotide compounds targeting the adenosine kinase pre-mRNA. These antisense oligonucletides are useful in the treatment of a range of neurological diseases, such as epilepsy or neuropathic pain. Compositions and methods of treating neurological diseases using the antisense oligonucleotides of the invention are provided.